1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 32

    Enumeration of TBNK cells: A case for a bioanalytical assay to support clinical studies for the development of modified risk tobacco products

    NEWLAND K.; MILLER P.; FARMEN R.
    Celerion, Inc., Lincoln, NE, U.S.A.
    Smoking has been reported to lessen the body’s immune response making it more susceptible to infections. Chronic cigarette smoke exposure causes imbalance in immune homeostasis affecting the circulating immune cells. Peripheral blood lymphocytes are...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 42

    Characterization of whole mainstream smoke/aerosol delivery within the Vitrocell® Ames 48 high throughput exposure module using different tobacco product types

    LEVERETTE R.(1); KEYSER B.(1); SEYMOUR A.(2); HOLLINGS M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, U.K.
    The preferred means of assessing combustible or other aerosol-generating tobacco products in vitro is by direct exposure of cell cultures to freshly generated whole mainstream smoke/aerosols. This approach eliminates the fractionation of...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in...
  4. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 049

    High throughput air liquid interface exposure modules: characterization of smoke/aerosol dosimetry and in vitro mutagenicity and cytotoxicity of two tobacco product types

    LEVERETTE R.(1); KEYSER B.(1); HOLLINGS M.(2); SEYMOUR A.(2)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) Covance Laboratories, North Yorkshire, UK
    The utilization of whole smoke/aerosol exposure systems provides a means to conduct in vitro assessments of freshly generated whole smoke/aerosol from combustible cigarettes and tobacco heating products (THPs), as well as electronic nicotine delivery...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 61

    Novel biomarkers to characterize exposure to aldehydes from e-vapor products based on stable-isotope constituents

    LANDMESSER A.(1); SCHERER M.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.S.(2); PLUYM N.(1)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    E vapor products (EVP) are an emerging category of non-combustible tobacco products that hold the promise of harm reduction for users of combustible products. Degradation products such as aldehydes have received much attention lately, however human...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 12 (also presented at TSRC 2018)

    Characterization of the Vitrocell® high throughput exposure modules using different tobacco product types

    LEVERETTE R.(1); KEYSER B.(2); SEYMOUR A.(2); HOLLINGS M.(2); BOMBICK B.(1)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    The development of whole smoke/aerosol exposure systems provides a means to conduct in vitro assessment of freshly generated whole smoke and aerosol from combustible and tobacco heating products (THP) as well as electronic nicotine delivery systems...
  9. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 13 (also presented at TSRC 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 1. Mouse lymphoma assay

    LEVERETTE R.(1); THORNE D.(2); BREHENY D.(2); FOWLER K.(1); McENANEY S.(3); LLOYD M.(3); CLEMENTS J.(3); BOMBICK B.(1); GACA M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) British American Tobacco (Investments) Ltd., Southampton, U.K.; (3) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    In vitro studies have been widely used to support the toxicological evaluation of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from different tobacco and nicotine delivery products was assessed...
  10. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 14 (also presented at TSRC 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 2. In Vitro micronucleus assay

    LEVERETTE R.(1); THORNE D.(2); BREHENY D.(2); FOWLER K.(1); McENANEY S.(3); WHITWELL J.(3); CLEMENTS J.(3); BOMBICK B.(1); GACA M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) British American Tobacco (Investments) Ltd., Southampton, U.K.; (3) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    In vitro studies have been widely used to support toxicological evaluations of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from tobacco and nicotine delivery products were assessed against a 3R4F...